Are portable ankle brachial pressure index measurement devices suitable for hypertension screening?
Are portable ankle brachial pressure index measurement devices suitable for hypertension screening?
复制标题
DOI：
10.1371/journal.pone.0283281
复制
发表时间：
2023
期刊：
影响因子：
3.7
通讯作者：
Chung, Emma M. L.
中科院分区：
文献类型：
--
作者：
Janus, Justyna;Nicholls, Jennifer K.;Pallett, Edward;Bown, Matthew;Chung, Emma M. L.
在大规模人群心血管筛查计划中，理想情况下可以使用单一设备快速评估外周动脉疾病 (PAD) 和高血压。踝臂压力指数 (ABPI) 是通过比较踝部和肱部血压 (BP) 来计算的。然而，目前尚不清楚自动 PAD 筛查系统提供的肱动脉血压测量对于同步高血压筛查是否足够准确。根据欧洲高血压学会国际协议 (ESH-IP) 2010 年修订版，使用无汞血压计作为参考设备，对两种便携式 PAD 筛查设备 MESI ABPI MD 和 Huntleigh’s Dopplex ABIlity 进行了评估。平均而言，MESI 略微低估了肱动脉收缩压 (BP)，偏差和标准差 (SD) 为 -3.5 (SD: 3.3) mmHg，舒张压偏差为 -1.5 (SD: 2.3) mmHg。对于收缩压估计，Dopplex 比 MESI 更准确，偏差较低，为 -0.5 (SD: 4.2) mmHg，但精度较低。 MESI 成功满足了 ESH-IP 对高血压筛查的所有要求。由于缺乏 DBP 测量，Dopplex 设备未通过 ESH-IP。 MESI 设备似乎适合同时进行 PAD 和高血压筛查，作为预防性护理计划的一部分。 Huntleigh 的 Dopplex ABIlity 未能通过 ESH-IP 验证测试。进一步的临床试验正在进行中，以评估 MESI 在人群筛查环境中同时筛查高血压和 PAD 的用途。
In a large-scale population cardiovascular screening programme, peripheral artery disease (PAD) and hypertension would ideally be rapidly assessed using a single device. The ankle-brachial pressure index (ABPI) is calculated by comparing the ankle and brachial blood pressure (BP). However, it is currently unclear whether brachial BP measurements provided by automated PAD screening systems are sufficiently accurate for simultaneous hypertension screening. Two portable PAD screening devices, the MESI ABPI MD and Huntleigh’s Dopplex ABIlity, were evaluated following the European Society of Hypertension International Protocol (ESH-IP) Revision 2010 using a mercury-free sphygmomanometer as a reference device. On average, the MESI slightly underestimated brachial systolic blood pressure (BP) with a bias and standard deviation (SD) of -3.5 (SD: 3.3) mmHg and diastolic BP with a bias of -1.5 (SD: 2.3) mmHg. For systolic BP estimates, the Dopplex was more accurate than the MESI with a lower bias of -0.5 (SD: 4.2) mmHg but less precise. The MESI successfully fulfilled all the requirements of the ESH-IP for hypertension screening. The Dopplex device failed the ESH-IP due to the absence of DBP measurements. The MESI device appears to be suitable for simultaneous PAD and hypertension screening as part of a preventative care programme. Huntleigh’s Dopplex ABIlity failed to pass the ESH-IP validation test. Further clinical trials are underway to assess the use of the MESI for simultaneous screening for hypertension and PAD in a population screening setting.
登录
查看更多内容
影响因子：
1.3
作者：
O'Brien, E;Pickering, T;Gerin, W
通讯作者：
Gerin, W
影响因子：
5.9
作者：
Hur KY;Jun JE;Choi YJ;Lee YH;Kim DJ;Park SW;Huh BW;Lee EJ;Jee SH;Huh KB;Choi SH
通讯作者：
Choi SH
影响因子：
5.4
作者：
Davies, Jane H.;Williams, E. Mark
通讯作者：
Williams, E. Mark
影响因子：
4.3
作者：
Hoyer, Christian;Sandermann, Jes;Petersen, Lars J.
通讯作者：
Petersen, Lars J.
影响因子：
1.3
作者：
O'Brien, Eoin;Atkins, Neil;Shennan, Andrew
通讯作者：
Shennan, Andrew